Document is current
Any future updates will be listed below
-
Authors
van Poelgeest, Eveline https://orcid.org/0000-0002-2021-5602
Prokopidis, Konstantinos
Erdogan, Tuğba https://orcid.org/0000-0001-8690-0189
Kwak, Min Ji https://orcid.org/0000-0003-2778-3984
Piotrowicz, Karolina https://orcid.org/0000-0002-4760-8588
Paoletti, Luca
Eidam, Annette https://orcid.org/0000-0002-1490-9456
Koçak, Fatma Özge Kayhan https://orcid.org/0000-0002-6447-2352
Ilhan, Birkan https://orcid.org/0000-0001-6039-5866
Beccacece, Alessia
Soulis, George https://orcid.org/0000-0002-2291-5733
Özkök, Serdar https://orcid.org/0000-0002-0994-1152
Bahat, Gulistan https://orcid.org/0000-0001-5343-9795
Topinková, Eva https://orcid.org/0000-0002-6786-4116
Daams, Joost https://orcid.org/0000-0002-8025-4961
Handoko, M. Louis https://orcid.org/0000-0002-8942-7865
Goyal, Parag
Gąsowski, Jerzy https://orcid.org/0000-0002-8025-5323
Cherubini, Antonio https://orcid.org/0000-0003-0261-9897
Veronese, Nicola https://orcid.org/0000-0002-9328-289X
Testa, Giuseppe Dario https://orcid.org/0000-0002-9157-3781
Thompson, Wade
van der Velde, Nathalie
,
- License Information
-
More Information
Article History
Received: 16 March 2025
Accepted: 30 April 2025
First Online: 25 May 2025
Declarations
:
: Min Ji Kwak received a research grant from the US Deprescribing Research Network, receives consult fees from Novo Nordisk, and owns stocks in Eli Lilly and Novo Nordisk. Louis Handoko is supported by a research grant of the Dutch Heart Foundation (NHS; 2020T058), the Amsterdam Cardiovascular Sciences (ACS) Institute, The Netherlands Organization for Scientific Research (NWO), and funding for an investigator-initiated study of Vifor Pharma. He received an educational grant and/or speaker/consultancy fees from Novartis, Boehringer Ingelheim, Daiichi Sankyo, Vifor Pharma, AstraZeneca, Bayer, MSD, and Abbott; all not related to this work. Parag Goyal is supported by National Institute on Aging grants K76AG064428 and R21AG077092. Dr. Goyal was a member of the Junior Investigator Intensive Program of the US Deprescribing Research Network and is supported by a US Deprescribing Research Pilot Grant, which are funded by the National Institute on Aging (R24AG064025). He has received consulting fees from Sensorum Health, Agepha Pharma, and Axon therapies; and has received personal fees for medicolegal consulting and expert testimony related to HF. Jerzy Gąsowski has given talks on the topic of anti-hypertensive therapy in older persons and deprescribing, some of which were associated with lecture fees. Wade Thompson has received grants for deprescribing research from Health Canada and the National Institute on Aging (US), is supported by a salary award from Michael Smith Health Research British Columbia; and receives an honorarium for writing an article on deprescribing in Pharmacy Practice Plus magazine. Eva Topinkova work was partly supported by the Project New Technologies in Translational Research in Pharmaceutical Sciences/NETPHARM reg. No. CZ.02.01.01/00/22_008/0004607, co-financed by the European Union. George Soulis has received consulting fees by Reckitt Benckiser for Advisory Board. All other authors have no conflict of interest to declare.
: N/A.
: For this type of study, formal consent is not required.
